The epidermal growth factor receptor (EGFR) is a tyrosine kinase (TK) receptor that is expressed in 40–80% of patients with NSCLC.8, 9 Due to the important role of EGFR in cellular growth and proliferation, it has been proposed as a target for NSCLC therapy10 and several EGFR inhibitors are being evaluated as treatment options for patients with advanced NSCLC.11 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.